Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Following heart attack patients with and without diabetes over time

Studies metabolic and heart changes in adults aged 18 to 80 after a heart attack.

Key facts

Who runs it
German Diabetes Center
Where
Düsseldorf, GermanySee the site
Trial code
Registry title
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Status
Recruiting
People taking part
300 people, planned
Started
30 Dec 2018
Expected to end
30 Dec 2029
Type of study
Observational, 3 groups
Record updated
22 August 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 18-80 who have just had a heart attack of the STEMI type. Some have diabetes, some prediabetes, some normal blood sugar.

Age
18 to 80 years
Sex
All sexes
Disease stage
New ST-segment elevation myocardial infarction (STEMI); stable blood circulation, able to give consent, and no sedating or other interfering medicines.
Earlier treatment
People cannot join if they take drugs that weaken the immune system or are in another intervention trial.
Biomarker or test result
HbA1c must be below 9.0% (75 mmol/mol). Blood sugar status is grouped by HbA1c and a sugar tolerance test (OGTT): diabetes, prediabetes, or normal.

Main reasons for not taking part

  • Other specific types of diabetes (category 3 A-H) or gestational diabetes
  • Current pregnancy
  • Infection or fever
  • Severe long-term kidney, liver or heart disease
  • Cancer or severe long-term mental illness or addiction

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Condition after new onset of ST-segment elevation myocardial infarction (STEMI)
  • Age 18-80 years
  • HbA1c <9.0%
  • People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and/or pathological oral glucose tolerance test)
  • Healthy people with normal glucose tolerance status according to ADA and DDG criteria (i.e. HbA1c <5.7% and normal OGTT)
  • People with impaired glucose metabolism ("prediabetes") according to ADA and DDG criteria (i.e. impaired fasting glucose and/or impaired glucose tolerance and/or HbA1c 5.7-6.4%)
  • Consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines)

Who cannot take part

  • Immunosuppressive therapy
  • Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes
  • Infectious diseases, acute infections / fever
  • Malignant diseases
  • Severe chronic psychiatric illness or addiction
  • Severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg/dl, peripheral artery occlusive disease stage IV)
  • Current pregnancy
  • Participation in an intervention trial

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in Germany

  • German Diabetes CenterDüsseldorf, GermanyContact: Clinical Study CenterTaking people

About the trial

What the trial wants to find out

The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.

The 3 groups in the trial

  • Cohort with type 1 diabetes (T1D) and type 2 diabetes (T2D)

    Prospectively followed cohort of people with new onset of ST-segment elevation myocardial infarction and diabetes mellitus (type 1 or type 2) according to the American Diabetes Association (ADA) and German Diabetes Society (DDG) criteria (HbA1c ≥6.5% or pathological oral glucose tolerance test (OGTT)), aged 18-80 years at inclusion into the study

  • Cohort of normal glucose tolerant people (NGT)

    Prospectively followed cohort of healthy people with new onset of ST-elevation myocardial infarction and normal glucose tolerance status (HbA1c \<5.7% and normal OGTT), aged 18-80 years at inclusion into the study

  • Cohort of people with impaired glucose metabolism (IGM)

    Prospectively followed cohort of people with new onset of ST-elevation myocardial infarction and impaired glucose metabolism, usually called prediabetes including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) and/or HbA1c 5.7-6.4%, aged 18-80 years at inclusion into the study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)
Plain-language title
Following heart attack patients with and without diabetes over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05046483, who can take part
Publications
Record updated
22 August 2023